FairJourney Biologics (FJBio), an antibody discovery contract research organisation, has appointed Werner Lanthaler as chief executive officer. The former CEO of Evotec joins the Portugal-based company to further strengthen its position as a highly efficient partner in antibody discovery and development. The company’s founder António Parada will drive FJBio’s innovation strategy on the supervisory board after leading the company for 14 years.
Dr Lanthaler’s 15 years at the helm of Evotec saw the company become a global leader in drug discovery, with a track record of building collaboration with global pharmaceutical, biotech and academic institutions. FJBio, in which private equity firm Partners Group invested in 2024, is expanding its internal machine learning platform, including establishing a dedicated Cryo-EM facility in San Diego, US, to advance rational antibody design.
FairJourney Biologics announced the appointment on 8 October 2025.
Copyright 2025 Evernow Publishing Ltd.